Clinical Trial Update: Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chemotherapy with bevacizumab and a PD-1 inhibitor in non-squamous non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Chemotherapy (chemotherapy)

Snippet

Sponsor: Qingdao Central Hospital | Conditions: PFS, OS | Phase 2 | Status: UNKNOWN